CD7-CART

CD7-CART is a Chimeric Antigen Receptor (CAR) T-cell therapy designed to treat CD7-positive hematological malignancies. This therapy involves genetically engineering a patient's (autologous) or a donor's (allogeneic) T-cells to express a CAR that specifically targets the CD7 protein, a transmembrane glycoprotein highly expressed in over 95% of T-cell acute lymphoblastic leukemia (T-ALL) and T-lymphoblastic lymphoma (T-LBL) cells, as well as in a subset of peripheral T-cell lymphomas and natural killer (NK) cells. A significant challenge in developing CD7-CART is preventing "fratricide," where the CAR-T cells, which also express CD7, attack each other. To overcome this, various strategies are employed, such as genetic deletion of the CD7 gene in the CAR-T cells (e.g., using CRISPR/Cas9) or utilizing protein expression blockers (PEBL) to prevent CD7 from being expressed on the CAR-T cell surface. Once re-infused into the patient, these engineered T-cells are designed to seek out and destroy CD7-expressing cancer cells.

Brand names

BEAM-201BEAM201BEAM 201WU-CART-007WU-CART007WU-CART 007

Other names

Anti-CD7 CAR T CellsAnti-CD-7 CAR T CellsAnti-CD 7 CAR T Cells